Vaxcyte, Inc. — Director's Dealing 2025

Feb 7, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2025-02-05

Reporting Person: Eydelman Mikhail (SVP, GEN COUNSEL & CORP SEC)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-05	Common Stock	M	5000	$21.41	Acquired	33222	Direct
2025-02-05	Common Stock	S	571	$87.767	Disposed	32651	Direct
2025-02-05	Common Stock	S	635	$89.088	Disposed	32016	Direct
2025-02-05	Common Stock	S	1755	$89.949	Disposed	30261	Direct
2025-02-05	Common Stock	S	1784	$91.052	Disposed	28477	Direct
2025-02-05	Common Stock	S	255	$91.708	Disposed	28222	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-05	Stock Option (right to buy)	$21.41	M	5000	Disposed	2032-05-08	Common Stock (5000)	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $87.405 to $88.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $88.52 to $89.385. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.

F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $89.53 to $90.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.

F5: The price reported is a weighted-average price. The shares were sold at prices ranging from $90.66 to $91.585. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.

F6: The price reported is a weighted-average price. The shares were sold at prices ranging from $91.69 to $91.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the
issuer, full information regarding the number of shares sold at each separate price.

F7: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.